|
|
International.
KLab has presence in 23 countries having registered more
than 50 products and more than 200 Dossiers are under
registration.
Regulated Markets (USA, EUROPE)
KLab is under negotiation of
outlicensing its Patented Products based
on NDDS, Nanotechnology, Dendrimers and Chiral Chemistry.
Non-Regulated Market (SOUTH
EAST, ASIA, AFRICA, LATIN
AMERICA, CIS ETC)
WHO-GMP Approved manufacturing facilities for Oncology,
General
tablets and cephalosporin.
Presently, KLab has operations in Nigeria, Ethiopia,
Kenya, Ghana, Zambia, Mozambique, Ivory Coast, Haiti,
Dominican Republic, Trinidad & Tobago, Iraq, Georgia,
Guatemala, Honduras, Myanmar, Thailand, Philippines, Hong
Kong, Cambodia, Vietnam, Sri Lanka, Maldives.
KLab expects to have its presence in Costa Rica, Ecuador,
Chile, Venezuela, Bolivia, Uganda, Tanzania, Yemen, Oman,
Jordan, Syria, Cameroon, Benin, South Africa, Pakistan,
Bhutan, Indonesia and Malaysia in near future, wherein
number of products are due for registration.
|
|
WHO-GMP
Approved manufacturing facilities
|
 |
|
WHO-GMP Approved manufacturing facilities for Oncology,
General tablets and cephalosporin.
|
| |
|
Markets
|
 |
|
Non-Regulated
(SOUTH EAST, ASIA, AFRICA, LATIN
AMERICA, CIS ETC)
|
| |
|
